Patents by Inventor Stéphane Silvente

Stéphane Silvente has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOUNDS DERIVED FROM STEROLS FOR THE TREATMENT OF A DISEASE ASSOCIATED WITH A MITOCHONDRIAL DEFICIT
    Publication number: 20260183311
    Abstract: A sterol-based compound of formula (I) for its use in preventing, ameliorating and/or treating a mitochondrial deficiency-related pathology chosen from the group consisting of autism, spinal cord injury, multiple sclerosis, epilepsy, migraine, alcohol-related mental pathologies, ataxia, neuropathies, smoking-related cerebral and pulmonary disorders, MERRF syndrome and NARP syndrome. A pharmaceutical composition comprising at least one compound of formula (I).
    Type: Application
    Filed: June 14, 2023
    Publication date: July 2, 2026
    Applicant: DENDROGENIX
    Inventors: Stéphane SILVENTE, Nicolas CARON, Arnaud RIVES, Quentin MARLIER, Hélène MICHAUX, Dario MOSCA, Maxime GILSOUL
  • PRODRUG OF 5a-HYDROXY-6ß-[2-(1H-IMIDAZOL-4-YL)ETHYLAMINO]CHOLESTAN-3ß-OL AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME FOR USE IN THE TREATMENT OF CANCER
    Publication number: 20240002429
    Abstract: The invention relates to a novel compound of general formula (I): and/or a pharmaceutically acceptable salt of a compound of this kind, a pharmaceutical composition comprising at least said compound, for use thereof as a drug for causing regression of a mammalian cancerous tumor.
    Type: Application
    Filed: December 3, 2021
    Publication date: January 4, 2024
    Applicant: DENDROGENIX
    Inventors: Stéphane SILVENTE, Quentin MARLIER, Arnaud RIVES, Nicolas CARON, Dario MOSCA, Hélène MICHAUX
  • 5ALPHA-HYDROXY-6BETA-[2-(1-H-IMIDAZOL-4-YL)-ETHYLAMINO]-CHOLESTAN-3BETA-OL ANALOGUES AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME FOR USE IN THE TREATMENT OF CANCER
    Publication number: 20230391817
    Abstract: The invention relates to a novel compound of general formula (I): and/or a pharmaceutically acceptable salt of such a compound, to a pharmaceutical composition comprising at least said compound, for its use as a medicament for shrinking a mammalian cancerous tumor.
    Type: Application
    Filed: October 28, 2021
    Publication date: December 7, 2023
    Applicant: DENDROGENIX
    Inventors: Stéphane SILVENTE, Quentin MARLIER, Arnaud RIVES, Nicolas CARON, Dario MOSCA, Hélène MICHAUX
  • Frozen ice cream dessert and process for making
    Patent number: 6558729
    Abstract: A frozen dessert which is spoonable at freezing temperatures and/or packageable in pressurized containers is disclosed. The frozen dessert has dairy proteins, fats, sweeteners, one or more stabilizing agents, flavoring agents or coloring agents. The proteins are provided by dairy milk products or skimmed milk. The fat is a vegetable oil with a very low freezing point. The sweeteners are a mixture of low molecular weight sweetening agents such as dextrose and/or fructose, invert sugar and glucose syrup.
    Type: Grant
    Filed: August 25, 1998
    Date of Patent: May 6, 2003
    Assignee: Nestec S.A.
    Inventors: Philippe Riviere, Stéphane Silvente, Frank Tonon, Veronique Andre-Linet